{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:09:33Z","timestamp":1793916573181,"version":"4.8.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cmi.2025.10.008","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T23:14:08Z","timestamp":1760656448000},"page":"365-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Optimizing antifungal therapies for Candida infections: evidence, resistance, and emerging approaches"],"prefix":"10.1016","volume":"32","author":[{"given":"Catriona","family":"Halliday","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Alguacil-Cu\u00e9llar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon C.-A.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alastruey-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.10.008_bib1","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1021\/acs.chemrev.0c00199","article-title":"Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond","volume":"121","author":"Lee","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.cmi.2025.10.008_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/antibiotics9060312","article-title":"Candidiasis and mechanisms of antifungal resistance","volume":"9","author":"Bhattacharya","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.10.008_bib3","doi-asserted-by":"crossref","first-page":"S445","DOI":"10.1093\/infdis\/jix131","article-title":"Multidrug-resistant candida: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Arendrup","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.10.008_bib4","doi-asserted-by":"crossref","first-page":"102208","DOI":"10.1016\/j.mib.2022.102208","article-title":"The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida auris","volume":"70","author":"Rybak","year":"2022","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.cmi.2025.10.008_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/524071","article-title":"Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact","volume":"46","author":"Kanafani","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.10.008_bib6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cmi.2019.03.028","article-title":"Resistance of Candida to azoles and echinocandins worldwide","volume":"25","author":"Pristov","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.10.008_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/myc.12330","article-title":"Antifungal drug resistance among Candida species: mechanisms and clinical impact","volume":"58","author":"Sanguinetti","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2025.10.008_bib8","first-page":"100341","article-title":"The evolution of antifungal therapy: traditional agents, current challenges and future perspectives","volume":"8","author":"Souza","year":"2025","journal-title":"Curr Res Microb Sci"},{"key":"10.1016\/j.cmi.2025.10.008_bib9","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.3390\/cells12222655","article-title":"Molecular mechanisms associated with antifungal resistance in pathogenic Candida species","volume":"12","author":"Czajka","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.cmi.2025.10.008_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s44259-023-00007-2","article-title":"Molecular mechanisms governing antifungal drug resistance","volume":"1","author":"Lee","year":"2023","journal-title":"NPJ Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.10.008_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1473-3099(02)00181-0","article-title":"Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences","volume":"2","author":"Sanglard","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.10.008_bib12","unstructured":"WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO https:\/\/www.who.int\/publications\/i\/item\/9789240060241. Accessed 6 February 2025."},{"key":"10.1016\/j.cmi.2025.10.008_bib13","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3389\/fmicb.2019.02788","article-title":"Review on antifungal resistance mechanisms in the emerging pathogen Candida auris","volume":"10","author":"Chaabane","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2025.10.008_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40588-024-00219-8","article-title":"Emerging antifungal resistance in fungal pathogens","volume":"11","author":"Hui","year":"2024","journal-title":"Curr Clin Microbiol Rep"},{"key":"10.1016\/j.cmi.2025.10.008_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/jof9010080","article-title":"Candida parapsilosis virulence and antifungal resistance mechanisms: a comprehensive review of key determinants","volume":"9","author":"Branco","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2025.10.008_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mmy\/myy054","article-title":"Candida auris: the recent emergence of a multidrug-resistant fungal pathogen","volume":"57","author":"Forsberg","year":"2019","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2025.10.008_bib17","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00662","article-title":"The evolution of drug resistance in clinical isolates of Candida albicans","volume":"4","author":"Ford","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.cmi.2025.10.008_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00074-23","article-title":"Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease","volume":"37","author":"Hoenigl","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2025.10.008_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/ph15040482","article-title":"Augmenting azoles with drug synergy to expand the antifungal toolbox","volume":"15","author":"Kane","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.cmi.2025.10.008_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.14740\/jocmr2992w","article-title":"Combination antifungal therapy: a review of current data","volume":"9","author":"Campitelli","year":"2017","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.cmi.2025.10.008_bib21","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1038\/s41598-020-64571-7","article-title":"Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species","volume":"10","author":"Eldesouky","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2025.10.008_bib22","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1093\/jac\/dkad303","article-title":"Exploring synergy between azole antifungal drugs and statins for Candida auris","volume":"78","author":"Halliday","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.10.008_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00121-24","article-title":"Spectrum of activity and mechanisms of azole\u2013bisphosphonate synergy in pathogenic Candida","volume":"12","author":"Kane","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.10.008_bib24","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3109\/13880209.2014.900808","article-title":"Possible mechanisms of the antifungal activity of fluconazole in combination with terbinafine against Candida albicans","volume":"52","author":"Khodavandi","year":"2014","journal-title":"Pharm Biol"},{"key":"10.1016\/j.cmi.2025.10.008_bib25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/myc.13203","article-title":"Alternative treatment of fungal infections: synergy with non-antifungal agents","volume":"64","author":"Rossato","year":"2021","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2025.10.008_bib26","article-title":"Synergistic effect of fluconazole and calcium channel blockers against resistant Candida albicans","volume":"11","author":"Liu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2025.10.008_bib27","doi-asserted-by":"crossref","first-page":"e02063-e19","DOI":"10.1128\/AAC.02063-19","article-title":"In vitro antifungal susceptibility of the emerging multidrug-resistant pathogen Candida auris to miltefosine alone and in combination with amphotericin B","volume":"64","author":"Wu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.10.008_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02086-23","article-title":"Efficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host model","volume":"12","author":"Hernando-Ortiz","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.10.008_bib29","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2666-5247(20)30090-2","article-title":"Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations","volume":"1","author":"O\u2019Brien","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2025.10.008_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/jof7020108","article-title":"In vitro characterization of twenty-one antifungal combinations against echinocandin-resistant and -susceptible Candida glabrata","volume":"7","author":"Khalifa","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2025.10.008_bib31","doi-asserted-by":"crossref","first-page":"e01056-17","DOI":"10.1128\/AAC.01056-17","article-title":"In vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris","volume":"61","author":"Fakhim","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.10.008_bib32","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Messer SA, Deshpande LM, Rhomberg PR, Utt EA, Castanheira M. Evaluation of synergistic activity of isavuconazole or voriconazole plus anidulafungin and the occurrence and genetic characterization of Candida auris detected in a surveillance program. Antimicrob Agents Chemother 2021;65:e02031. https:\/\/doi\/org\/10.1128\/aac.02031-20","DOI":"10.1128\/AAC.02031-20"},{"key":"10.1016\/j.cmi.2025.10.008_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01645-22","article-title":"Heightened efficacy of anidulafungin when used in combination with manogepix or 5-flucytosine against Candida auris in vitro","volume":"67","author":"John","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.10.008_bib34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11046-023-00788-0","article-title":"Synergy in vitro of nikkomycin Z with azole against the invasive form of Candida albicans","volume":"188","author":"Sass","year":"2023","journal-title":"Mycopathologia"},{"key":"10.1016\/j.cmi.2025.10.008_bib35","doi-asserted-by":"crossref","first-page":"e00619-17","DOI":"10.1128\/AAC.00619-17","article-title":"Effects of echinocandins in combination with nikkomycin Z against invasive Candida albicans bloodstream isolates and the fks mutants","volume":"61","author":"Cheung","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.10.008_bib36","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3390\/antibiotics11111601","article-title":"Synergistic interaction of caspofungin combined with posaconazole against FKS wild-type and mutant Candida auris planktonic cells and biofilms","volume":"11","author":"Balla","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.10.008_bib37","first-page":"859","article-title":"In vitro combination therapy with isavuconazole against Candida spp","volume":"55","author":"Katragkou","year":"2017","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2025.10.008_bib38","doi-asserted-by":"crossref","unstructured":"de Bastiani FWMDS, Spadari C de C, de Matos JKR, Salata GC, Lopes LB, Ishida K. Nanocarriers provide sustained antifungal activity for amphotericin B and miltefosine in the topical treatment of murine vaginal candidiasis. Front Microbiol 2020;10:2976. https:\/\/doi.org\/10.3389\/fmicb.2019.02976","DOI":"10.3389\/fmicb.2019.02976"},{"key":"10.1016\/j.cmi.2025.10.008_bib39","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1128\/AAC.49.12.4895-4902.2005","article-title":"Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin","volume":"49","author":"Olson","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.10.008_bib40","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/jof9040434","article-title":"In vitro\u2013in vivo correlation of posaconazole\u2013amphotericin B combination against Candida albicans: In vitro interacting concentrations are associated with in vivo free drug levels","volume":"9","author":"Meletiadis","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2025.10.008_bib41","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/mmy\/myab032","article-title":"In vitro and in vivo interaction of caspofungin with isavuconazole against Candida auris planktonic cells and biofilms","volume":"59","author":"Nagy","year":"2021","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2025.10.008_bib42","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/jof8101077","article-title":"Antifungal combinations against Candida species: from bench to bedside","volume":"8","author":"Fioriti","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2025.10.008_bib43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijantimicag.2003.10.005","article-title":"Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr","volume":"23","author":"Gil-Lamaignere","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.10.008_bib44","unstructured":"Therapeutics, REZZAYO M. (rezafungin for infection), for intravenous use. Prescribing information. https:\/\/rezzayo.com\/wp-content\/pdfs\/REZZAYO%20(rezafungin%20for%20injection)%20Package%20Insert.pdf Accessed 10 June 2025."},{"key":"10.1016\/j.cmi.2025.10.008_bib45","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for Candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.10.008_bib46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14787210.2019.1592675","article-title":"Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients","volume":"17","author":"Ruiz-Gait\u00e1n","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2025.10.008_bib47","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/jpc.15019","article-title":"Neonatal Candida auris infection: management and prevention strategies\u2014a single centre experience","volume":"56","author":"Chandramati","year":"2020","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.cmi.2025.10.008_bib48","unstructured":"Siebert RS, Juneja D, Nguyen MH, Vazquez J, Azie NE, Angulo DA. Outcomes of oral ibrexafungerp in subjects with urinary tract infections from two phase 3 open-label studies: difficult-to-treat invasive fungal infections (FURI) and infections with Candida auris (CARES) Presented at:. 33rd European congress of clinical microbiology & infectious diseases (ECCMID); 2023. Copenhagen, Denmark. Abstract MEM0404 https:\/\/www.scynexis.com\/wp-content\/uploads\/2023\/04\/ECCMID-2023-UTI-Poster-Landscape-Final.pdf. Accessed 10 June 2025"},{"key":"10.1016\/j.cmi.2025.10.008_bib49","unstructured":"ClinicalTrials.gov. An open-label study of APX001 for treatment of candidaemia\/invasive candidiasis caused by Candida auris (APEX). https:\/\/ichgcp.net\/clinical-trials-registry\/NCT04148287. Accessed 10 June 2025"},{"key":"10.1016\/j.cmi.2025.10.008_bib50","unstructured":"ClinicalTrials.gov. A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult participants with candidemia and\/or invasive candidiasis. https:\/\/clinicaltrials.gov\/study\/NCT05421858. Accessed 10 June 2025"},{"key":"10.1016\/j.cmi.2025.10.008_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.10.008_bib52","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.10.008_bib53","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/jof8050440","article-title":"The feasibility of ibrexafungerp for the treatment of fungal infections in patients with hematological malignancies","volume":"8","author":"Daraskevicius","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2025.10.008_bib54","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/jof8101102","article-title":"Calcineurin inhibitors synergize with manogepix to kill diverse human fungal pathogens","volume":"8","author":"Liston","year":"2022","journal-title":"J Fungi (Basel)"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:20:53Z","timestamp":1785363653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25005099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1198743X25005099"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.10.008","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing antifungal therapies for Candida infections: evidence, resistance, and emerging approaches","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}